This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Use of acetazolamide for symptoms of visual vertigo

Use of acetazolamide for symptoms of visual vertigo
Reviewed by Claire Howard

1 June 2018 | Claire Howard | EYE - Neuro-ophthalmology | Acetazolamide, dizziness, visual vertigo

Visual vertigo is a disorder characterised by symptoms of dizziness, vertigo, unsteadiness, disorientation and general discomfort induced by visual triggers. It is currently treated with vestibular rehabilitation therapy, with no effective pharmacotherapy options available for treatment resistant case. Oral acetazolamide has been reported to improve symptoms of dizziness in some patients. The authors present a study evaluating the efficacy of oral acetazolamide in improving symptoms of visual vertigo. Adult patients clinically diagnosed with the condition between 1992 and 2015 were identified and contacted to complete a symptom survey. The participants were then retrospectively divided into three groups based on their treatment with acetazolamide: currently on the drug, terminated the drug, or never initiated the drug. Fifty-seven patients were included in the study (19 currently on acetazolamide, 27 terminated use and five who never initiated therapy). Overall symptomatic improvement was reported by 18 (94.7%) patients currently on acetazolamide, 18 (66.7%) who terminated acetazolamide and five (45.5%) who never initiated therapy, varying significantly by group (p=0.0061). The authors discuss these results and suggest that acetazolamide has a positive association with improvement of symptoms of visual vertigo. The study has limitations with its retrospective nature, with the authors discussing this as a possible area of future research using a multi-centre randomised controlled trial to support the association further.

Acetazolamide: a new treatment for visual vertigo.
Sluch IM, Elliott MS, Dvorak J, et al.
NEURO-OPHTHALMOLOGY
2017;41(6):315-20.
Share This
CONTRIBUTOR
Claire Howard

Salford Royal NHS Foundation Trust, Salford, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency